Parambir S. Dulai and Corey A. Siegel* Pages 740 - 747 ( 8 )
Treatment strategies and treatment options have changed considerably over the past decade for Inflammatory Bowel Disease (IBD). Alongside this shift in therapeutic options has come an opportunity to personalize treatment decisions based on individual patient profiles and preferences. One of the most important aspects of therapy in IBD is treatment related risk, and an opportunity exists to personalize therapy through optimization of drug safety profiles in individual patients. In this review we discuss the potential risks of therapy in IBD, opportunities to mitigate those risks, and a personalized approach to consider when using these agents in clinical practice.
Crohn's disease, ulcerative colitis, risk, adverse events, inflammatory bowel disease, infections
University of California San Diego, San Diego, CA, Dartmouth-Hitchcock Medical Center, Lebanon, NH